Abstract
The clinical applications of PET have been determined only recently. Reimbursement for clinical PET studies has a major effect on the utilization of PET. The research applications of PET are well documented, but the clinical applications of PET are not as well accepted. Reimbursement for clinical studies is limited to a few specific indications by a small number of private insurance companies at this time. The Health Care Financing Administration (HCFA) has referred the review of PET to the Office of Health Technology Assessment (OHTA). HCFA administers Medicare, and thus reimbursement from the Federal Government will be determined by HCFA. HCFA and OHTA have determined that they will not complete their review until the radiopharmaceuticals are approved by the Food and Drug Administration (FDA). Rubidium-82 is an FDA-approved radiopharmaceutical, but F-18-fluorodeoxyglucose (FDG) has not been approved by the FDA as yet. Thus, significant uncertainty still is present in the status of reimbursement by the Federal Government.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
R.E. Coleman, M.S. Robbins, and B.A. Siegel, The future of PET in clinical medicine and the impact of drug regulation, Semin Nucl Med. 12:193–201 (1992).
R.E. Coleman, W.H. Briner, and B.A. Siegel, Clinical PET scanning: a “shortlived” orphan, Intl J Technol Assess Health Care. 8(4):610–622 (1992).
D.E. Kuhl, H.N. Wagner, A. Alavi, R.E. Coleman, S.M. Larson, M.A. Mintun, B.A. Siegel, and P.K. Strudler, Positron emission tomography (PET): clinical status in the United States in 1987, J Nucl Med. 29:1136–1143 (1988).
M. Al-Aish, R.E. Coleman, S.M. Larson, et al, Advances in clinical imaging using positron emission tomography, National Cancer Institute Workshop Statement, Arch Int Med. 150:735–739 (1990).
R.E. Coleman, SPECT and PET in cancer imaging, Cancer. 67:1261–1270 (1991).
E.F. Patz, V. Lowe, J.M. Hoffman, S. Paine, P. Burrows, R.E. Coleman, and P.C. Goodman, Evaluation of focal pulmonary abnormalities with 18F-fluoro-2-deoxy-glucose and positron emission tomography, Radiology. 188:487–490 (1993).
J.M. Hoffman, M.W. Hanson, and R.E. Coleman, Clinical positron emission tomography (PET) imaging, Radiol Clin N Am. 31:935–960 (1993).
R.E. Coleman, Will clinical PET become a reality?, Nucl Med Comm. 14:407–410 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Coleman, R.E. (1995). PET: The Governmental Reimbursement Perspective. In: Emran, A.M. (eds) Chemists’ Views of Imaging Centers. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9670-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9670-4_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9672-8
Online ISBN: 978-1-4757-9670-4
eBook Packages: Springer Book Archive